Bathi resik saben saham (EPS TTM) Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (RARE) is optimizing its development by outsourcing drug manufacturing and testing to third-party contractors. This chart of the annual EPS TTM captures the impact of such a strategy on profitability, where -5.21 serves as the final level marker. A stable team of scientists maintains the brand's ethics, yet revenue deficits and R&D expenses are leading to the depletion of reserves and a search for external financing.
Rincian metrik keuangan lan pasar Ultragenyx Pharmaceutical (RARE)

For the biotechnology sector of Ultragenyx Pharmaceutical (RARE), where Crysvita revenue growth and FDA approvals drive capitalization, this indicator serves as a measure of real efficiency in generating earnings per share. By analyzing the rolling year net income per share, an investor sees smoothed profitability trends without the influence of one-off reports, allowing for an objective assessment of the company's potential as an M&A target.